Clinician Education Hub

Liver Disease

Chronic Liver Diseases

As the prevalence of obesity, type 2 diabetes, and the opioid crisis in the United States continues to rise, so does chronic liver disease. From hepatitis C and hepatitis B to non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), liver disease affects a significant portion of the U.S. population. Hepatitis C virus (HCV) is a leading cause of cirrhosis, liver cancer, and mortality worldwide. Injection drug use, arising in conjunction with the opioid crisis, has contributed significantly to the increase in HCV infections. Chronic hepatitis B virus (HBV) remains a global epidemic, resulting in significantly increased morbidity and mortality. Furthermore, the rising number of obese and diabetic patients has resulted in the increased prevalence of NAFLD, which may progress to NASH in a large number of patients. To help clinicians and patients navigate the changing landscape of liver disease, we designed the Liver Disease Hub to provide resources and guidelines for screening, testing, and treatment of liver disease.

Educational Activities

Launch Date

Addressing the Unmet Needs of Patients with Acute Hepatic Porphyria

In this activity, experts in AHP provide practical and patient-centered guidance for optimizing screening, diagnosis, and treatment.


Educating Frontline Clinicians to Reduce Missed Opportunities for HBV Screening

In this recorded CME Outfitters webcast, expert faculty focus on universal HBV screening with triple panel testing to accurately identify patients with active HBV infection.


Mitigating Progression of Liver Fibrosis in HIV/HCV Coinfection

This CMEO BriefCase will introduce a complex case involving treatment and management considerations for a patient with HIV and HCV. Join Drs. Nancy Reau and Christian Ramers as they explore the epidemiology and shared pathobiology of liver fibrosis in HIV/HCV, real-world data for available therapies, contraindicated agent combinations, and when and how to treat.


Treatment Selection in a Patient with Decompensated Cirrhosis

This CMEO BriefCase will introduce a case involving the incorporation of routine surveillance for HCC in a patient with HCV. Join our faculty experts as they delve into the epidemiology and shared pathobiology of HCV and decompensated cirrhosis, identify compensated versus decompensated cirrhosis, and discuss surveillance strategies for HCC.